Endovascular lower-extremity revascularization procedures performed by interventional radiologists bring about less transfusion and intensive-care unit use, shorter hospital stays, fewer repeat revascularization procedures, fewer amputations, and lower costs compared to those done by vascular surgeons.
Endovascular lower-extremity revascularization procedures performed by interventional radiologists bring about less transfusion and intensive-care unit use, shorter hospital stays, fewer repeat revascularization procedures, fewer amputations, and lower costs compared to those done by vascular surgeons.
So concludes a study published in the January 2012 edition of the Journal of Vascular and Interventional Radiology that considered data from 14,000 Medicare patients.
Authors said this study is the first and largest of its kind on peripheral arterial disease (PAD) treatments for Medicare patients age 65 and older. PAD is a narrowing of the blood vessels in the leg, which limits the supply of oxygen and nutrients to the leg, causing pain and discomfort. It affects an estimated 10 million people in the United States (12 percent to 20 percent of Americans over age 65) and can lead to heart attack or stroke.
The team found the potential cost savings to be substantial.
"We noted that the adjusted average one-year procedure cost when performed by interventional radiologists was about $17,640. That's a cost savings to Medicare of approximately $1,000 per procedure – which means that in such a large population, treatments for PAD by interventional radiologists could potentially save taxpayers $230 million each year. And the patient outcomes are better," said Timothy Murphy, MD, an interventional radiologist and director of the Vascular Disease Research Center at Rhode Island Hospital in Providence.
Murphy and colleagues reviewed Medicare claims data from more than 14,000 patients with PAD from 2005 to 2007 from Medicare's Standard Analytical Files, a large dataset that contains all services (physician, inpatient, and outpatient). The authors compared outcomes of percutaneous PAD treatments in Medicare patients according to the physician specialty type (interventional radiologist, interventional cardiologist, vascular surgeon) and assessed mortality, transfusion, intensive care use, length of stay, and subsequent restoration of blood supply or amputation.
Murphy said the study provided strong evidence that treatment by interventional radiologists provides numerous benefits to the PAD patient, such as less risk of infection, less anesthesia, less pain and scarring, faster recovery and a quicker return to normal activities.
“The Medicare data clearly show more transfusion and intensive care utilization, longer length of stay, more repeat procedures or amputations and higher costs when treatment is not performed by interventional radiologists," Murphy said.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Expanded FDA Approval Allows Use of Pluvicto Prior to Chemotherapy in Patients with mCRPC
March 28th 2025Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).
New AI-Enabled Portable Ultrasound May Facilitate 50 Percent Reduction in Cardiac Imaging Scan Time
March 28th 2025Artificial intelligence (AI)-powered measurement capabilities provide key features with the Compact Ultrasound 5500CV device, which will be unveiled at the American College of Cardiology (ACC) conference.